|
| Exchange Disseminated Time | Bliss GVS Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2015, inter alia, has considered and approved the followings:
1. Declared Final Dividend at the rate of 50% i.e. Re. 0.50 per share.
2. Sale of Step Down subsidiary “Surgimed Pharma Limited” located at Kenya;
3. Due to ill health Mr. G.G Desai resigned from the Board;
4. Re-appointment of the Statutory Auditor of the Company;
5. Appointment of Secretarial Auditor for the financial year 2015-2016;
6. Appointment of Internal Auditor of the Company for the financial year 2015-16;
7. Adopted the Secretarial Audit report, Board report, Auditors report & Notice of the forthcoming Annual General Meeting;
8. Code of Prevention and Prohibition of Insider Trading in Securities of the Company under SEBl (Prohibition of Insider Trading) Regulation, 2015. |
|
|